'Conservative' pharmaceutical industry slow to take advantage of online marketing opportunities

While the internet has altered the landscape in the retail sector and revolutionized the airline industry, pharmaceutical companies have been slow to take advantage of the marketing opportunities offered by the medium. With existing sales and marketing strategies widely considered unsustainable, the industry needs to evolve and engage with its customers online, or it risks being left behind. 

Drug Repositioning Strategies - Serendipity by design

Drug repositioning has several advantages over traditional discovery-reduced cost, risk and time to market-compared with traditional discovery, providing an attractive prospect for Big Pharma, scrambling to fill pipelines in an increasingly harsh market environment. As competition to inlicense candidates drives the price of this strategy up, repositioning presents a cost effective alternative.

Osteoarthritis - The COX-2 pipeline collapses

With several recent non-approvable decisions in the osteoarthritis market since 2006, Datamonitor has updated its forecast to account for the effect on the market. We have revised the market outlook over the next 10 years using the latest IMS data. We expect the market to grow steadily, with a CAGR from 2007 to 2017 of 3.2%, to reach sales of nearly $5.5 billion in 2017.

Acute Stroke: Commercial risk offsets high unmet need

Stroke is one of the top three causes of death and its incidence in the seven major markets is expected to increase in the next ten years because of an aging population. Long term disability caused by stroke is a major economic burden on healthcare systems, current treatment options are limited and general awareness of stroke is poor.

Online Patient Recruitment Strategies - Optimizing the clinical trial process

With the rising costs, length and complexity of clinical trials, drug development is subject to huge delays, translating into delays in getting a drug to market and millions of dollars in lost sales. Optimizing the recruitment process through web-based technologies can cut delays in clinical trials and can also be used to maintain relationships with patients to improve the clinical trial process.

Non-insulin antidiabetics – Incretin mimetics – leaders in a diverse pipeline

Datamonitor expects incretin mimetics to emerge as a major new therapeutic class in non-insulin antidiabetics, driven by an explosion in the patient population, safety fears surrounding established therapies and significant unmet patient needs.

Pricing & Reimbursement - Seven Major Markets Update

Governments and payers across the seven major markets are implementing cost-cutting initiatives to combat escalating healthcare costs, putting even greater pressure on pharma companies. In addition to the credit crunch, ever fewer novel products are coming to market, contributing to the declining return on investment.

Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

Innovative Clinical Trial Design and Management is a report published by Business Insights that explores the major types of adaptive design and their role in dose-finding. The report investigates seamless Phase 2/3 trials and adaptive trials in pharmacogenomics, assesses the logistical implications of adaptive trial implementations and reviews the current regulatory standpoints of the FDA and EMEA.

The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends

Emerging Role of Postmarketing Clinical Research is a report published by Business Insights that uses detailed case studies and market scenarios to examine the latest issues surrounding phase IV trial applications. The potential to leverage competitive advantage with postmarketing research is assessed by measuring the implications for formulary access, product marketing, indication expansion and reimbursement coverage.

Market developments, technology transfer and key success factors

Contract Manufacturing Strategies is a report published by Business Insights that explores the future of the contract manufacturing market with a detailed analysis of emerging drivers and restraints, business models and production strategies.

Drug distribution restricted as manufacturers attempt to guard supply chain

Ideally, drug supply should be a simple and transparent chain that connects the manufacturer and patient in as few steps as possible. However, in practice, this is rarely the case. Manufacturers are trying to exercise greater control over the supply chain and cut the number of intermediaries; however, a recent European Commission recommendation could put a stop to many of these efforts.

Potential lung cancer epidemic looming in Asia

Regulatory Issues - Europe continues to make strides while the US lags behind

The drive for increased cost savings by healthcare providers is increasing the focus on boosting the biosimilar market. With a regulatory approval pathway in place in Europe and substantial guidelines to support biosimilar development, the European biosimilars market is significantly more advanced than the US, where plans for a biosimilar regulatory approval pathway have stalled.

Chinese Pharmaceutical Market Overview - Regulatory reform and the evolving healthcare market provide

The Chinese pharmaceutical market, although only positioned ninth globally, has experienced pronounced and rapid expansion in recent years, driven by the growth of both Chinese and Western manufacturers. Increasingly, there is a shift towards a research-based industry, focused on generating new, innovative therapies, supported by improving intellectual property regulations.

Antithrombotics - Pipeline products to dampen the impact of patent expiries and cost containment initiatives

The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.

Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan

After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era.

Gynecological Cancers - Niche opportunities in advanced disease

Cases of endometrial cancer are set to rise in developed countries due to an increase in risk factors such as obesity. In contrast, while incidence of cervical cancer is set to decrease in developed countries following the implementation of anti-HPV immunization with Merck & Co's Gardasil and GlaxoSmithKline's Cervarix, it will remain a major cause of cancer-related death in the developing world.

Pricing and Reimbursement in Oncology - Do payers believe oncology drugs offer good value?

The oncology market has shown remarkable growth in recent years, driven by the advent of targeted therapy and the high level of unmet needs in the disease, and it is poised for further expansion. While this will provide companies with opportunities, a key hurdle for novel cancer drugs will be the increasing pharmacoeconomic vigilance that prevails within cash-strapped healthcare systems.